TABLE 3.
Information about and after radium‐223 treatment
| Total number of radium‐223 cycles (n, %) | |
| 1 | 12 (8) |
| 2 | 18 (11) |
| 3 | 44 (28) |
| 4 | 15 (9) |
| 5 | 12 (8) |
| 6 | 59 (37) |
| Median (range) | 4 (1–6) |
| Reason of discontinuation (n, %) | |
| 6 cycles of radium‐223 | 59 (37) |
| Progressive disease (PD) | 56 (35) |
| Toxicities | 34 (21) |
| Preplanned cycles less than 6 given | 4 (3) |
| Other a | 5 (3) |
| Unknown | 2 (1) |
| Treatments after radium‐223 (n, %) | |
| Docetaxel | 11 (7) |
| Cabazitaxel | 35 (22) |
| Abiraterone | 25 (16) |
| Enzalutamide | 38 (24) |
| Other b | 6 (4) |
| Palliative radiotherapy for bone pain after radium‐223 treatment (n, %) | |
| Yes | 76 (48) |
| No | 84 (53) |
| Skeletal‐related events (n, %) | |
| Yes | 13 (8) |
| No | 139 (87) |
| Unknown | 8 (5) |
a
Traumatic cerebral hemorrhage (2 patients, no thrombocytopenia), headache/ocular symptoms (2 patients, later orbital or visceral metastases detected), and acute death due to unknown cause after the first radium‐223 cycle.
b
177Lutetium‐PSMA, 153Samarium‐EDTMP, combination of mitoxantrone and prednisone or estramustine.